An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Clinical trial NCT04597632 · COMPLETED
Trial details
- NCT number
- NCT04597632
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-16
- Primary completion
- 2023-03-28
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.